Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.

Ikeda M, Shiina S, Nakachi K, Mitsunaga S, Shimizu S, Kojima Y, Ueno H, Morizane C, Kondo S, Sakamoto Y, Asaoka Y, Tateishi R, Koike K, Arioka H, Okusaka T.

Invest New Drugs. 2014 Oct;32(5):928-36. doi: 10.1007/s10637-014-0109-2. Epub 2014 May 15.

2.

Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer.

Koizumi W, Yamaguchi K, Hosaka H, Takinishi Y, Nakayama N, Hara T, Muro K, Baba H, Sasaki Y, Nishina T, Fuse N, Esaki T, Takagi M, Gotoh M, Sasaki T.

Br J Cancer. 2013 Oct 15;109(8):2079-86. doi: 10.1038/bjc.2013.555. Epub 2013 Sep 17. Erratum in: Br J Cancer. 2014 Dec 9;111(12):2382.

3.

A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy.

Shin SJ, Jung M, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC, Ahn JB.

Invest New Drugs. 2012 Aug;30(4):1501-10. doi: 10.1007/s10637-011-9683-8. Epub 2011 May 13.

PMID:
21567184
4.

A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.

Lee J, Shin SJ, Chung IJ, Kim TW, Chun HG, Shin DB, Kim YH, Song HS, Han SW, Kim JG, Kim SY, Choi YJ, Chung HC.

Invest New Drugs. 2014 Jun;32(3):561-8. doi: 10.1007/s10637-014-0075-8. Epub 2014 Feb 27.

PMID:
24573743
5.

Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.

Lee SJ, Lee J, Park SH, Park JO, Park YS, Kang WK, Lee J, Yim DS, Lim HY.

Invest New Drugs. 2012 Aug;30(4):1540-7. doi: 10.1007/s10637-011-9706-5. Epub 2011 Jun 22.

PMID:
21695438
6.

Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.

Boku N, Muro K, Machida N, Hashigaki S, Kimura N, Suzuki M, Lechuga M, Miyata Y.

Invest New Drugs. 2014 Apr;32(2):261-70. doi: 10.1007/s10637-013-9948-5. Epub 2013 May 12.

7.

Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma.

Furuse J, Okusaka T, Kaneko S, Kudo M, Nakachi K, Ueno H, Yamashita T, Ueshima K.

Cancer Sci. 2010 Dec;101(12):2606-11. doi: 10.1111/j.1349-7006.2010.01730.x. Epub 2010 Oct 14.

8.

Pilot study of systemic combination therapy with S-1, an oral fluoropyrimidine, and cisplatin for hepatocellular carcinoma with extrahepatic metastases.

Katamura Y, Aikata H, Hashimoto Y, Kimura Y, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Chayama K.

Hepatogastroenterology. 2010 Sep-Oct;57(102-103):1272-8.

PMID:
21410071
9.

A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.

Ooka Y, Chiba T, Ogasawara S, Arai K, Suzuki E, Tawada A, Yamashita T, Kanai F, Kaneko S, Yokosuka O.

Invest New Drugs. 2014 Aug;32(4):723-8. doi: 10.1007/s10637-014-0077-6. Epub 2014 Mar 7.

PMID:
24599799
10.

Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.

Okamoto I, Yoshioka H, Takeda K, Satouchi M, Yamamoto N, Seto T, Kasahara K, Miyazaki M, Kitamura R, Ohyama A, Hokoda N, Nakayama H, Yoshihara E, Nakagawa K.

J Thorac Oncol. 2012 Feb;7(2):427-33. doi: 10.1097/JTO.0b013e318238154d.

11.

Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial.

Terazawa T, Kondo S, Hosoi H, Morizane C, Shimizu S, Mitsunaga S, Ikeda M, Ueno H, Okusaka T.

BMC Cancer. 2014 Apr 30;14:301. doi: 10.1186/1471-2407-14-301.

12.

Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.

Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J, Nishiyama M, Toge T.

Anticancer Res. 2004 May-Jun;24(3b):1843-51.

13.

Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.

Chu QS, Hammond LA, Schwartz G, Ochoa L, Rha SY, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, DeCillis AP, Rowinsky EK.

Clin Cancer Res. 2004 Aug 1;10(15):4913-21.

14.

A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance.

Toi M, Saeki T, Iwata H, Inoue K, Tokuda Y, Sato Y, Ito Y, Aogi K, Takatsuka Y, Arioka H.

Breast Cancer. 2014 Jan;21(1):20-7. doi: 10.1007/s12282-012-0344-3. Epub 2012 Mar 2.

PMID:
22382811
15.

Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.

Satoh T, Yamada Y, Muro K, Hayashi H, Shimada Y, Takahari D, Taku K, Nakajima TE, Shi X, Brown KH, Boku N.

Cancer Chemother Pharmacol. 2012 Feb;69(2):439-46. doi: 10.1007/s00280-011-1723-8. Epub 2011 Aug 19.

PMID:
21853311
16.

Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma.

Kim SJ, Han SW, Oh DY, Yi NJ, Kim YJ, Im SA, Yoon JH, Kang GH, Suh KS, Bang YJ, Jang JJ, Kim TY.

Anticancer Res. 2010 Dec;30(12):5245-50.

PMID:
21187521
17.

A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation.

Inaba Y, Kanai F, Aramaki T, Yamamoto T, Tanaka T, Yamakado K, Kaneko S, Kudo M, Imanaka K, Kora S, Nishida N, Kawai N, Seki H, Matsui O, Arioka H, Arai Y.

Eur J Cancer. 2013 Sep;49(13):2832-40. doi: 10.1016/j.ejca.2013.05.011. Epub 2013 Jun 10.

PMID:
23764238
18.

Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial.

Kim SB, Yoo C, Ro J, Im SA, Im YH, Kim JH, Ahn JH, Jung KH, Song HS, Kang SY, Park HS, Chung HC.

Invest New Drugs. 2014 Aug;32(4):753-61. doi: 10.1007/s10637-014-0093-6. Epub 2014 Apr 9.

PMID:
24715580
19.

Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases.

Uka K, Aikata H, Mori N, Takaki S, Kawakami Y, Azakami T, Kawaoka T, Jeong SC, Takahashi S, Chayama K.

Oncology. 2008;75(1-2):8-16. doi: 10.1159/000151614. Epub 2008 Aug 22.

PMID:
18719349
20.

Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.

Tsujitani S, Fukuda K, Kaibara N.

Gastric Cancer. 2003;6 Suppl 1:50-7.

PMID:
12775021

Supplemental Content

Support Center